UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial

PloS one, 2017-07, Vol.12 (7), p.e0180762-e0180762

2017

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

Proceedings of the National Academy of Sciences - PNAS, 2017-03, Vol.114 (10), p.E1825-E1832

2017

Link zum Volltext

Verfügbarkeit prüfen

A potent Lassa virus antiviral targets an arenavirus virulence determinant

PLoS pathogens, 2018-12, Vol.14 (12), p.e1007439-e1007439

2018

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of alpha 9 alpha 10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

Proceedings of the National Academy of Sciences - PNAS, 2017-03, Vol.114 (10), p.E1825-E1825

2017

Link zum Volltext

Verfügbarkeit prüfen

Kv1.3 blockade by ShK186 modulates CD4+ effector memory T-cell activity of patients with granulomatosis with polyangiitis

Rheumatology (Oxford, England), 2024-01, Vol.63 (1), p.198-208

2024

Link zum Volltext

Verfügbarkeit prüfen

1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1511-A1511

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway

Journal of virology, 2016-03, Vol.90 (5), p.2372-2387

2016

Link zum Volltext

Verfügbarkeit prüfen

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Frontiers in immunology, 2023-12, Vol.14, p.1311658-1311658

2023

Link zum Volltext

Verfügbarkeit prüfen

Extracellular 2′-5′ Oligoadenylate Synthetase Stimulates RNase L-Independent Antiviral Activity: a Novel Mechanism of Virus-Induced Innate Immunity

Journal of Virology, 2010-11, Vol.84 (22), p.11898-11904

2010

Link zum Volltext

Verfügbarkeit prüfen

780 VISTA-101 – A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A877-A877

2023

Link zum Volltext

Verfügbarkeit prüfen

Kv1.3 channel‐blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases

The FASEB journal, 2014-09, Vol.28 (9), p.3952-3964

2014

Link zum Volltext

Verfügbarkeit prüfen

Isoflavone Agonists of IRF-3 Dependent Signaling Have Antiviral Activity against RNA Viruses

Journal of Virology, 2012-07, Vol.86 (13), p.7334-7344

2012

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Frontiers in immunology, 2024, Vol.15, p.1365240-1365240

2024

Link zum Volltext

Verfügbarkeit prüfen

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease

The Journal of pharmacology and experimental therapeutics, 2012-09, Vol.342 (3), p.642

2012

Link zum Volltext

Verfügbarkeit prüfen

Association of the FTO Gene With BMI

Obesity (Silver Spring, Md.), 2008-04, Vol.16 (4), p.902-904

2008

Link zum Volltext

Verfügbarkeit prüfen

Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance

Proceedings of the National Academy of Sciences - PNAS, 2013-06, Vol.110 (24), p.E2239-E2248

2013

Link zum Volltext

Verfügbarkeit prüfen

Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis

Frontiers in immunology, 2017-09, Vol.8, p.1205-1205

2017

Link zum Volltext

Verfügbarkeit prüfen

Genomics Hepatitis C virus gets personal

Nature (London), 2009-09, Vol.461 (7262), p.357-358

2009

Link zum Volltext

Verfügbarkeit prüfen

879 A promising cancer immunotherapy target: novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A921-A921

2021

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C virus gets personal

Nature (London), 2009-09, Vol.461 (7262), p.357-358

2009

Link zum Volltext

Verfügbarkeit prüfen

High-density rhesus macaque oligonucleotide microarray design using early-stage rhesus genome sequence information and human genome annotations

BMC genomics, 2007-01, Vol.8 (1), p.28-28, Article 28

2007

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macaca and human

Genome biology, 2005, Vol.6 (7), p.R60-R60

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract P035: A promising cancer immunotherapy target: Novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27

Cancer immunology research, 2022-01, Vol.10 (1_Supplement), p.P035-P035

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1637: A fully human anti-vista antibody as a promising therapy against poorly immunogenic tumors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1637-1637

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract A60: CD27 an emerging immuno-oncology target at the cross-roads of innate and adaptive anti-tumor immune responses

Cancer immunology research, 2022-12, Vol.10 (12_Supplement), p.A60-A60

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 40

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(39)
Dissertationen
(1)

Sprache

Englisch
(40)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Humans
(15)
Life Sciences & Biomedicine
(13)
Animals
(10)
Immunotherapy
(6)
Mice
(6)
Female
(4)
Immunology
(4)
Kv1.3 Potassium Channel - Antagonists & Inhibitors
(4)
Male
(4)
Multidisciplinary Sciences
(4)
Science & Technology - Other Topics
(4)
Virology
(4)
Biological And Medical Sciences
(3)
Cytokines - Metabolism
(3)
Fundamental And Applied Biological Sciences. Psychology
(3)
Genetics
(3)
Genetics & Heredity
(3)
Ligands
(3)
Lymphocytes
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial

Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

A potent Lassa virus antiviral targets an arenavirus virulence determinant

Inhibition of alpha 9 alpha 10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

Kv1.3 blockade by ShK186 modulates CD4+ effector memory T-cell activity of patients with granulomatosis with polyangiitis

1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody

Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Extracellular 2′-5′ Oligoadenylate Synthetase Stimulates RNase L-Independent Antiviral Activity: a Novel Mechanism of Virus-Induced Innate Immunity

780 VISTA-101 – A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors

Kv1.3 channel‐blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases

Isoflavone Agonists of IRF-3 Dependent Signaling Have Antiviral Activity against RNA Viruses

Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease

Association of the FTO Gene With BMI

Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance

Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis

Genomics Hepatitis C virus gets personal

879 A promising cancer immunotherapy target: novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27

Hepatitis C virus gets personal

High-density rhesus macaque oligonucleotide microarray design using early-stage rhesus genome sequence information and human genome annotations

Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macaca and human

Abstract P035: A promising cancer immunotherapy target: Novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27

Abstract 1637: A fully human anti-vista antibody as a promising therapy against poorly immunogenic tumors

Abstract A60: CD27 an emerging immuno-oncology target at the cross-roads of innate and adaptive anti-tumor immune responses

Aktive Filter

Suchergebnisse filtern